Skip to main content

Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Miquel Vila Bover

Miquel Vila Bover

Miquel Vila Bover

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Projects

Pathogenic role of neuromelanin in Parkinson’s disease and brain aging: molecular mechanisms in a novel humanized pre-clinical in vivo model

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Michael J. Fox Foundation
Funding: 86064.99
Reference: TARGET.ADV_MJFF2018 M.VILA
Duration: 01/06/2018 - 30/05/2019

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

IP: Miquel Vila Bover
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 96843.15
Reference: BES-2017-080191
Duration: 01/07/2018 - 30/11/2022

Lewy body extracts from parkinson's disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 35200
Reference: 2017SGR1806
Duration: 01/01/2017 - 30/09/2021

Rol de la neuromelanina en la enfermedad de Parkinson y del envejecimiento cerebral: estudio `ptemcoañ terpéutico en nuevos modelos preclínicos "humanizados" in vivo.

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Rol de la neuromelanina en la enfermedad de Parkinson y del envejecimiento cerebral: estudio `ptemcoañ terpéutico en nuevos mode
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 363000
Reference: SAF2016-77541-R
Duration: 30/12/2016 - 29/12/2020

Related news

The nomination recognises the work she has led together with Dr. Núria Peñuelas and Dr. Miquel Vila, on the generation of new preclinical models to study Parkinson's disease.

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Helena Xicoy Cortada

Helena Xicoy Cortada

Postdoctoral researcher
Neurodegenerative Diseases
Read more
Mario Marotta Baleriola

Mario Marotta Baleriola

Main researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Enrique Jose Montagut Cañete

Enrique Jose Montagut Cañete

Predoctoral researcher
Microbiology
Read more
Victor  Barro  Ojeda

Victor Barro Ojeda

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.